ArticleInternational journal of molecular sciences2023

Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report.

Douglas Dias E Silva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.